Evidence map›Paper›PMID 42403873›Full record

ArticleCureus2026

First-Trimester Serum Omentin Levels as a Predictor of Gestational Diabetes Mellitus.

Abhigya Malik, Sheeba Marwah, Megha Arora, Nidhi Verma, Drashya Khatri, Archana B S, Amandeep Kaur, Muskan Bhalla, Bindu Bajaj

Abstract read
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abhigya MalikDepartment of Obstetrics and Gynaecology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND.
Sheeba MarwahDepartment of Obstetrics and Gynaecology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND.
Megha AroraDepartment of Biochemistry, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND.
Nidhi VermaDepartment of Obstetrics and Gynaecology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND.
Drashya KhatriDepartment of Obstetrics and Gynaecology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND.
Archana B SDepartment of Obstetrics and Gynaecology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND.
Amandeep KaurDepartment of Obstetrics and Gynaecology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND.
Muskan BhallaDepartment of Obstetrics and Gynaecology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND.
Bindu BajajDepartment of Obstetrics and Gynaecology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, IND.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGestational diabetes mellitus (GDM) is a frequent metabolic complication of pregnancy associated with significant maternal and neonatal morbidity. Its prevalence is notably higher among South Asian women, likely due to increased baseline insulin resistance and genetic predisposition. Conventional screening using the oral glucose tolerance test (OGTT), typically performed at 24-28 weeks of gestation, often identifies GDM after metabolic alterations are already established, thereby limiting opportunities for early intervention. This has led to growing interest in identifying reliable first-trimester biomarkers for early risk prediction. Adipokines, which play a crucial role in metabolic regulation and inflammation, have emerged as promising candidates. Omentin, an insulin-sensitizing adipokine predominantly secreted by visceral adipose tissue, has been implicated in glucose homeostasis. This study aimed to evaluate first-trimester serum omentin levels as a predictor of GDM and to assess its association with fetomaternal outcomes.

methodsA prospective cohort study was conducted over a period of 18 months from July 2024 to December 2025 at Vardhman Mahavir Medical College (VMMC) and Safdurjung Hospital. Pregnant women aged 18-35 years with a singleton pregnancy and a normal two-hour OGTT at their first antenatal visit were enrolled. First-trimester venous blood samples were collected under standardized conditions, and serum omentin levels were measured using enzyme-linked immunosorbent assay (ELISA). Participants underwent repeat 75-g OGTT at 24-28 weeks and again at 32-34 weeks of gestation. All participants were followed until delivery to monitor the development of GDM and to document relevant maternal and neonatal outcomes.

resultsLower first-trimester serum omentin levels were significantly associated with subsequent development of GDM and demonstrated moderate predictive utility on receiver operating characteristic curve (ROC) analysis, with an area under the receiver operating characteristic curve (AUROC) of 0.683. At the optimal cutoff value, specificity was 83%, and the negative predictive value was 90.8%, indicating a strong capacity to identify women at low risk for developing GDM. A trend toward increased adverse fetomaternal outcomes was observed among women with lower omentin levels.

conclusionsFirst-trimester serum omentin shows promise as an early predictive biomarker for GDM. Its incorporation into routine antenatal screening protocols may improve early risk stratification and facilitate timely preventive interventions. These findings support the potential role of adipokine-based screening strategies in enhancing current approaches to GDM detection and improving overall pregnancy outcomes.

Indexed as

adipokinesfirst trimestergestational diabetes mellitusogttomentinpredictive biomarkers

Identifiers

PMID42403873
PMCPMC13330415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.